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SUMMARY 
The development of new anticancer agents derived from natural resources requires a 
rapid identification of their molecular mechanism of action. To make this step short we 
have initiated the proteomic profiling of HeLa cells treated with the anticancer drugs 
representing a wide spectrum of mechanisms of action, using 2D-DIGE. A unique 
proteome patterns were observed in HeLa cells treated with the HSP90 inhibitor, 
geldanamycin, and those were similar to the patterns induced by radicicol, another 
structurally different HSP90 inhibitor. On the other hand, etoposide and ICRF-193, the 
compounds claimed to be topoisomerase II inhibitors, showed different proteomic 
profiles, which reflect their different biological activities as revealed by cell cycle 
analysis. So far combined data from 19 compounds allowed their successful classification 
by cluster analysis according to the mechanism of action.  
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INTRODUCTION 
Cell based assays are widely used in drug discovery because the assessment of 
molecular interaction occurs within the context of a living cellular environment (Baker, 
et al., 2007). Many bioactive compounds, inhibiting the growth of cancer cells, have been 
isolated using a cell-based screen (Kakeya, et al., 2002; Kawada, et al., 2009). In most 
instances, the molecular target for newly isolated compounds remained unknown. The 
identification of a plausible target is sometimes possible based on the results of cell-based 
assays, however, the exact target must be proven by enzymatic assays, analyses of 
binding proteins, or genetic methods employing a siRNA (Kazami, et al., 2006; Sato, et 
al., 2007; Teruya, et al., 2005). The confirmation of the molecular targets, however, is 
usually a difficult and time-consuming process.  
The multidimensional phenotype profiling approaches have a capacity to generate a 
testable hypothesis related to the mechanism of action and eventual off-target effects of 
new compounds. The differential sensitivity of the panel of cancer cell lines to the 
compounds has been used to identify their molecular target(s). The most commonly used 
assay, NCI 60 antitumor screen, allowed to identify benzolactone enamide as an inhibitor 
of V-ATPase (Boyd, et al., 2001). The other panel consisting of 39 different cancer cell 
lines identified the compound encoded as ZSTK474 to be the inhibitor of 
phosphatidylinositol 3-kinase (Yaguchi, et al., 2006). Recent advances in the field of 
molecular biology provided a wide spectrum of methods suitable for target identification. 
The application of the connectivity map, developed by Golub and co-workers that uses 
gene expression signature for profiling (Lamb, et al., 2006), led to the identification of a 
class of HSP90 pathway modulators (gedunin and celastrol) (Hieronymus et al 2006). 
The cell morphology-based profiling (Abassi, et al., 2009; MacDonald, et al., 2006) and 
the activity-based proteomic profiling (Leung, et al., 2003) are also used for molecular 
target identification. 
 Compared with gene expression profiling which can simultaneously measure the 
expression of more than 20,000 genes, proteome analysis provides us only with the 
opportunity to trace at most 1,000 protein spots. However, any change of molecular 
weight and isoelectric point of proteins after posttranslational modification is often 
detectable as a mobility shift of protein spots in two-dimensional gel electrophoresis 
(2DE) analyses.  Since biologically active compounds affect cellular processes and 
induce changes in both the expression levels and modification of proteins, proteome 
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profiling is an informative approach for investigating the effects of the compound. Indeed, 
several research groups have shown that biologically active compound alter the proteome 
(Cecconi, et al., 2007; Towbin, et al., 2003). Recent advances in two-dimensional 
difference gel electrophoresis (2D-DIGE) have allowed to measure the abundance of 
each protein spot between different gels with a high accuracy due to introduction of an 
internal standard (Van den Bergh and Arckens, 2004). With 2D-DIGE, the abundant 
proteomic expression data obtained from different treatments can be collected, and the 
expression patterns can be compared. In this study, we have used 2D-DIGE to perform a 
comprehensive proteome analysis of protein expression changes caused by the treatment 
of cancer cells with the anticancer drugs claimed to possess the “exact mechanisms of 
action”. 
 It is well known that the anticancer drugs of known and similar mechanism of 
action such as doxorubicin and daunorubicin, both classified as anthracyclines, are 
clinically active against different types of cancers. Doxorubicin is mainly used in the 
treatment of solid tumors, while daunorubicin shows activity in hematologic 
malignancies. The other case is cisplatin and oxaliplatin, the former active against lung 
and ovarian cancers, and the latter active against colon cancer. Keeping in mind a subtle 
difference in clinical activity of the compounds of similar “exact mechanism of action”, 
we have made an attempt to establish differential proteins profiles in cancer cells treated 
with anticancer agents representing several main mechanisms of action, including also 
several compounds possessing the same well-established mechanism of action. The 
proteomic profiling of mechanism of action may play essential role in the planning of 
individualized chemotherapy of cancer patients, once the correlation between drug 
sensitivity and the drug-induced proteomic profile is found. 
 Here, we report the procedure and results of the proteome analysis, using 2D-DIGE 
that revealed significant similarities in protein expression changes induced by the 
compounds belonging to the same class. Furthermore, we were also able to distinguish 
subtle differences among compounds attacking the same molecular target, however, in a 
different way.  
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RESULTS 
Proteomic Patterns of Geldanamycin and Radicicol-Treated HeLa Cells are Similar  
Geldanamycin (1) and radicicol (2) are well-known HSP90 inhibitors (Schulte, et 
al., 1998; Whitesell, et al., 1994). HSP90 is one of the targets for cancer therapeutics, and 
17-AAG, a derivative of geldanamycin is under clinical trials (Nowakowski, et al, 2006). 
First, we have determined cell growth inhibitory effect of HSP90 inhibitors against HeLa 
cells using a WST-8 assay (Fig. 1A). The IC50 growth inhibitory concentration of 
geldanamycin against HeLa cells was approximately 0.05 µM in a 48-h treatment. HeLa 
cell growth was not affected at concentrations lower than 0.01 µM, while a complete 
growth inhibition was observed at concentrations greater than 0.1 µM. The IC50 of 
radicicol against HeLa cell growth was approximately 1 µM. 
Next, we have investigated the relationship between proteomic changes after 
exposing HeLa cells to effective concentrations of the compounds, e. g., 0.005, 0.05, 0.5, 
5, and 10 µM for geldanamycin and 10 µM for radicicol; the results are shown in Fig. 1B. 
In this analysis, 775 spots in 2DE gels were matched on all gel images and quantified by 
2D-DIGE system software, resulting in 282 spots that were selected by ANOVA (P < 
0.01) and Dunnett’s test (P < 0.01) (see Table S1). Then, hierarchical cluster analysis was 
performed. The results were displayed in the form of a heat map and a tree diagram (Fig. 
1B). In the heat map, the spots with increased expression are indicated in red, and the 
spots with decreased expression are indicated in green. As indicated in the tree diagram 
and the heat map, the patterns of protein expression were similar at geldanamycin 
concentrations greater than 0.5 µM. 
To simplify the statistical evaluation of the 2D-DIGE experiments, the spots that 
were modified significantly between groups were typically selected using ANOVA test 
and a volume ratio filter of no less than 2-fold for 3 biological replicates per group (Karp 
and Lilley, 2005). Using these parameters, 17 spots were selected and a similar result for 
the cluster analysis was obtained (data not shown). 
In HSP90 inhibitor-treated cells, HSP70 and HSP27 have been reported to be 
upregulated (Maloney, et al., 2007; McCollum, et al., 2006). To classify test compounds 
using proteomic profiling, the identity of each protein spot is not necessary, however, it is 
important to confirm whether proteomic change of geldanamycin-treated cell matches 
that in previously reported results. Peptide mass fingerprinting identified 20 spots out of 
the total number of spots that had been significantly affected by the treatment with 
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geldanamycin and other compounds (Table S2 and S3). The application of ANOVA test 
selected 15 out of 20 spots and the mean ratios between control and inhibitor-treated cells 
were tabulated (Table 1). 
Spots 1114 and 1127, which were identified as heat shock 70 kDa protein 1 (HSP70, 
HSPA1B), were upregulated more than 7-fold when compared with control. At 0.05 µM 
geldanamycin, HSP70 upregulation was also detected, but the magnitude of increase was 
lower compared with higher concentrations. The expression level of spot 2382, identified 
as heat shock protein beta-1 (HSP27, HSPB1), also reached a plateau, as did HSP70. By 
Western blot, both HSP70 and HSP27 were upregulated to similar extent at 
concentrations greater than 0.05 µM (Fig. 1C). 
The upregulation of mitochondrial heat shock proteins (HSP9B, HSPD1) and 
protein disulfide isomerase and downregulation of eukaryotic elongation factor 2 (EEF2), 
fascin (FSCN1), adenylyl cyclase-associated protein 1 (CAP1), and aldo-keto reductase 
family 1 member C2 (AKR1C2) were observed in geldanamycin-treated HeLa cells. It is 
very important to indicate that the concentration corresponding to the IC50 in the WST-8 
assay is insufficient to induce any obvious changes in the proteomic analysis. It is more 
reasonable to use concentrations at which cell growth is nearly completely inhibited.  
When the cells were exposed to 0.5 µM geldanamycin, the amount of HSP70 
increased in time-dependent manner and reached a plateau after 18 h (Fig. 1 D and E). 
Since long incubation with test compounds may be associated with secondary effects, 
such as apoptosis, we purposely avoided long exposures. Instead, we performed a 
subsequent proteomic analysis of HeLa cells after 18 h exposure to test compound. 
Radicicol (2) is another HSP90 inhibitor that structurally differs from geldanamycin 
(1). The expression patterns between radicicol- and geldanamycin-treated cells were 
compared by 2D-DIGE. Similar responses were observed between geldanamycin- and 
radicicol-treated cells (Fig. 1B and Table 2). HSP70 (nos. 1114 and 1127), HSP27 (nos. 
2372 and 2382) and 78 kDa glucose-regulated protein (GRP78, HSPA5; nos. 972 and 
983) increased during both treatments (Table 2). The spots representing eukaryotic 
elongation factor 2, fascin, and adenylyl cyclase-associated protein 1 were 
downregulated during both treatments. These results strongly suggest that compounds 
inhibiting the same molecular target generate similar proteomic profiles. 
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Proteomic Analysis of HeLa Cells Treated with Compounds of Known Mechanisms 
of Action 
To compare the proteomic patterns in HeLa cells treated with the compounds whose 
targets are known, the well-characterized chemical entities were selected for proteomic 
analysis (Table 2). Based on experience with geldanamycin, the proteomic analysis of 
above mentioned compounds was performed at the concentrations higher than their 
respective IC50 values.  Their growth inhibitory effects were determined by WST-8 assay 
and are presented as the IC50 values in Table 2.  The concentrations used for the exposure 
of HeLa cells during proteomic profiling experiments were those inhibiting cell growth 
by 80% or more (Table 2).   
 As previously indicated, the proteomic analyses of HeLa cells were performed after 
18 h exposure to a test compound. Since the master gel of geldanamycin-treated cells 
from the previous experiment (Fig. 2A) was used as the template, the numbering of the 
spots remained the same in all experiments. Three hundred eighteen spots in the 2DE-gel 
were matched on all gel images, and quantified by 2D-DIGE software; 298 of them were 
selected by ANOVA (P < 0.01) and Dunnett’s test (P < 0.01) (see Table S4). The data 
were calculated and visualized by cluster analysis programs (Fig. 2B); the mean ratio of 
the identified spots and the results of statistical analysis are listed in Table 4. 
 As indicated in the tree diagram (Fig. 2B), the inhibitors of V-ATPase (bafilomycin 
A1 and concanamycin A), tubulin (nocodazole and vinblastine), and actin (cytochalasin 
D and jasplakinolide) were classified into separate clusters. The spots that changed 
significantly between groups were selected using ANOVA and a volume ratio filter of no 
less than 2-fold (Karp and Lilley, 2005), yielding 47 spots and leading to a similar result 
of cluster analysis (data not shown).  
We also noticed that MG-132, a proteasome inhibitor, generated a similar pattern as 
the HSP90 inhibitors did. The amount of protein in the HSP70 spots (spots 1114 and 
1127) also increased in MG-132-treated cells, as did those observed in geldanamycin- 
and radicicol-treated cells (Table 3). In contrast, the HSP27 showed an aberrant pattern. 
Although HSP90 inhibitors increased the amount in spots 2372 and 2382, which were 
identified as HSP27, the MG-132 treatment increased only the spot number 2372. 
Other noteworthy changes were as follows: 1) the inhibitors of actin, cytochalasin 
D and jasplakinolide increased the amount of actin (spots 1758 and 1767); 2) tunicamycin 
increased the spot 983, identified as GRP78, 4.6-fold compared with control; 3) 
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ICRF-193 and antimicrotubular agents, such as nocodazole and vinblastine, decreased 
the amount of lamin (970 and 978) in consequence forming one cluster; and 4) the potent 
protein kinase inhibitor staurosporine downsized the spots 714 (EEF2), 970 (LMNA), 
1227 (HNRNPK), 1429 (CAP1), and 1484 (FSCN1), while expanding the spots 983 
(HSPA5), 998 (HSPA9B), 1295 (HSPD1), 1767 (ACTG1), and 2382 (HSPB1).  
Iejimalides, 24-membered macrolides, were originally isolated from marine tunicate 
as potent antitumor compounds (Nozawa, et al., 2006). We recently found that 
iejimalides inhibited V-ATPase (Kazami, et al., 2006). We have analyzed HeLa cells 
treated with iejimalide A (3) or iejimalide B (4) at 30 nM by 2D-DIGE. We combined the 
proteome data from iejimalides-treated HeLa and compared with the proteomic profiles 
generated by the treatment of HeLa cells with 19 well-characterized compounds. 
Iejimalide A (3) and B (4) were clustered into the same tree as the other V-ATPase 
inhibitors (e.g., bafilomycin A1 (5) and concanamycin A (6)) (Fig. 2C). Recently, it was 
reported that iejimalides affect actin depolymerization (Fürstner, et al., 2007), however, 
iejimalide A and B did not match the cluster representing actin inhibitors. These results 
indicate that the primary target of iejimalides in HeLa cells is V-ATPase, at least at 
concentration used in our experimental setting. 
 
Flow Cytometry of HeLa Cells Treated with ICRF-193 and Etoposide  
The proteomic analysis of HeLa cells treated with the two structurally different 
inhibitors of topoisomerase II (topo II), ICRF-193 (7) and etoposide (8) revealed 
significant differences; both compounds were not able to form a single cluster (Fig. 2B). 
To confirm this finding, we measured the distribution of cellular DNA in HeLa cells by 
flow cytometry, after treating asynchronous HeLa cells with varying concentrations of 
ICRF-193 or etoposide for 48 h. 
The basic amount of DNA in a haploid nucleus is given the value C. In the absence of 
inhibitors, we observed typical 2 peaks, corresponding to cell population with 2C and 4C 
DNA content. The treatment of HeLa cells with ICRF-193 resulted in decreasing the 
height of the 2C peaks at concentrations higher than 1 µM, while the 4C population 
increased (Fig. 3A). On the other hand, etoposide used at concentrations higher than 1 
µM also increased the 4C peaks, but without any obvious accumulation of the peaks 
containing 8C DNA, contrasting the effect of ICRF-193 (Fig. 3B). 
 9 
The kinetics of the shifts from the diploid to tetraploid DNA cellular contents was 
also studied in time-dependent fashion, using equimolar concentration of 10 µM for both 
test compounds. The ICRF-193 induced a gradual accumulation of 4C population up to 
18 hour, then the generation of polyploidy (8C) in HeLa cells was observed (Fig. 3C) 
beyond that time point. 
Etoposide was not able to induce polyploidy in HeLa cells, even during 72-h 
exposure (Fig. 3D). Despite the presence of common mechanism of action (topo II 
inhibition), the final biological effects are different, and two compounds were clustered 
into different cluster in our proteomic analysis. 
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DISCUSSION 
 In this study, we have performed a proteomic analysis of HeLa cancer cells treated 
with well-characterized anticancer agents using a 2D-DIGE system. The target proteins 
of these compounds are known at the cellular level and represent the targets for cancer 
therapeutics, such as the proteasome and microtubules. Each compound induced a 
characteristic proteomic pattern and hierarchical clustering exactly classified the 
compounds according to their respective targets, such as HSP90, tubulin and V-ATPase 
(Fig 2B).  
Topo II inhibitors are still good candidates for molecular targeted drugs in cancer 
therapy. Topo II as a single target can be inhibited by two distinct mechanisms. One is 
exercised by a catalytic site inhibition, resulting in the formation of a non-cleavable 
complex and is characteristic for ICRF-193, a topo II inhibitor (7) (Roca, et al., 1994; 
Tanabe, et al., 1991). The other mechanism involves the stabilization of DNA cleavable 
complex, which further leads to double-strand DNA breaks and damage; etoposide (8), a 
topo II poison, plays essential role in this mechanism (Liu, 1989). As reported by Ishida et 
al., etoposide blocked the progression of cells to M phase, while ICRF-193 only delayed 
the transition from S to M phase and induced polyploidization in HeLa cells (Ishida, et al., 
1994). Thus, both compounds are topo II inhibitors but act through disparate mechanisms 
(Andoh and Ishida, 1998). Their proteomic phenotypes differed and did not fall into the 
same cluster. Moreover, their cellular phenotypes, as determined by the analysis of 
cellular DNA distribution (Fig. 3) differed as well. One may conclude that such 
compounds can be classified into different clusters from proteomic point of view, despite 
exercising their biological activity through the same molecular target, or their exact 
mechanism of action may be revised.  An inability to share a common cluster might be 
caused by an excessive off-target effect. To clarify that matter it seems important to know 
which mechanism determines anticancer activity against particular type of cancer or 
contributes mainly to toxicity. Gathering more data will be of a great importance in the 
evaluation of undesired effects as well.  
So far, our proteomic profiling of mechanism of action of anticancer agents appeared 
to be helpful in the identification of the mode of action of iejimalides, a newly isolated 
natural products, as being inhibitors of V-ATPase (Fig. 2C). The comparison of the 
proteomes of the cells treated with a newly isolated compound versus well-characterized 
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compounds can lead to the testable hypothesis on general mechanisms of action as in the 
case of other profiling approaches such as the genetic one.  
Despite of recent enthusiasm, one may anticipate certain limitations of our proteome 
profiling system. To name a few, the following factors may become the obstacle in the 
system. 1) The suspected target for test compound is not expressed or is not functional 
(mutation, SNP) in HeLa cells. 2) The suspected target was not validated yet by known 
standards. 3) The changes induced in proteomic profile by a test compound are not 
sufficiently distinct due to the appearance of limited number of spots in 2D gels. 4) The 
presence of several molecular targets may complicate the analysis; therefore, an 
interpretation of data will have to be made with great caution.   
Our proteomic analysis matched methyl-gerfelin with two V-ATPase inhibitors, 
however, its biological effects in cell system (upregulation of pH, Figure S1) were not 
confirmed. The newly developed by us technology of a small molecule affinity matrix, 
revealed a strong interaction with glyoxalase I, supposedly a direct target molecule 
(Kawatani et al., 2008). The lack of standards for glyoxalase I inhibitors in proteomic 
analysis led to the clustering with the V-ATPase inhibitors. Therefore, the expansion of 
the system by variety of compounds with increased precision and accuracy of the system 
in classifying compounds into groups will lead to the well-established mechanism of 
action. The compounds not matching any known mechanisms may be considered as the 
probes for searching not yet  identified molecular targets. 
 The case of jasplakinolide  and cytochalasin D may well illustrate some of the 
obstacles, both compounds affect actin by inhibiting its depolymerization (Bubb, et al., 
1994) and polymerization (Cooper, 1987), respectively. Although their effects on actin 
are opposed, both compounds increased the levels of actin and were included into the 
same cluster in this experiment. However, we noted the presence of several unidentified 
spots that did not correlate to these two compounds. Further investigation should clarify 
the differences between polymerizing and depolymerizing effects of these two inhibitors 
with the application of  proteomic analysis.  
The 2DE-based proteomic analysis is generally a time-consuming process during the 
initial stage of system development, since the identification of almost all protein spots is 
essential. Once this stage is completed and a database is created, one can analyze the 
proteomic profiles of many chemical entities by comparing them with those contained in 
the database, without necessity of additional protein spots identification. This is a huge 
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advantage of this technique. Nevertheless, in the case of dramatic change in the 
expression levels among not yet identified spots, the characterization of those spots will 
be very informative in target identification, or at least these compound-specific spots may 
serve as an important marker of biological activity. The agents inducing microtubules 
depolymerization may serve as an illustration of where a compound does not directly 
cause the modification of a protein spot, and is rather an artifact related to its primary 
mechanism of action. More specifically, the antimicrotubular agents cause cell cycle 
arrest in M-phase, preventing cell division due to the lack mitotic spindle formation and 
the nuclear envelope remains intact. Under normal condition the envelope is broken down 
and its component, lamin, is released (Parnaik, 2008).  The release of lamin is decreased 
after the exposure of the cells to antimicrotubular agents (Table 3) and may serve as a 
marker of compound’s effectiveness, albeit, not being a target.  
The treatment of HeLa cells with MG-132 increased the expression of HSP70, thus 
confirming already reported phenomenon (Kawazoe, et al., 1998) and the cluster analysis 
tree positioned this compound close to the group of HSP90 inhibitors. However, slight 
differences were observed, namely, HSP90 inhibitors increased both spots of HSP27 (nos. 
2372 and 2382), while the MG-132 increased only spot number 2372. Because HSP27 
has been reported to enhance proteasome-dependent protein degradation (Parcellier, et al., 
2006; Parcellier, et al., 2003), this result may suggest the presence of at least two forms of 
HSP27, one of which is probably involved in proteasome-dependent protein degradation. 
Based on these results, we propose that the expression levels of HSP27 spots may 
determine the classification of compounds either to HSP90 inhibitor or to proteasome 
inhibitor class of compounds. Particularly, the expression ratio of HSP70 and HSP27 
spots will play a role of differentiating marker for either class.  
So far, we have examined only 19 compounds, reaching an ability to classify the 
compounds according to their mechanism of action. The expansion of the proteomic 
profiling by the other types of compounds with different mode of action will make the 
system fully operating for the prediction of biological activity of newly discovered 
natural products or synthetic compounds. Already, we were able to classify a newly 
synthesized derivative of natural product with unknown mechanism of action as an 
inhibitor of topoisomerase II (data not shown). For that purpose, the extensive process of 
system validation using the chemical library of NPDepo (Tomiki, et al., 2006) is under 
way. Since the assay is primary based upon the only one cancer cell line, it is reasonable 
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to include the other cell lines, especially when the obvious differences in drug responses 
among cell line are observed. As the natural consequence of the recent promising results, 
there is the need to include protein interaction map that should enforce the discovery of 
new target molecules. One may easily indicate a protein spot which may become a 
marker, however, one should explore the path from the marker up to the protein 
responsible for that change; then the protein may be claimed to be a target, or in other 
words, the object of a primary attack by an active substance.   
In summary, the proteomic profiling based on the 2D-DIGE is an important 
supplement to other multidimensional phenotypic profilings and its capacity may be 
extended by the introduction of the different pathological phenotypes represented by 
cancer cells, leading, e.g., to identification of specific biomolecules as well.   
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SIGNIFICANCE 
 New natural compounds, possessing important biological activity, had been subjected to 
extensive and time-consuming processes to clarify main mechanism of action. In order to 
reduce the time for target identification, we set up the faster method based on a 2D-PAGE 
characteristic proteomic patterns of HeLa cells treated with various compounds. The 
compounds such as geldanamycin and radicicol, representing diverse structures but 
sharing common target, were classified in the same tree by cluster analysis. The 
iejimadiles A and B, were reported to affect depolymerization of actin, however, were not 
clustered together with actin inhibitors, instead were clustered into a group of V-ATPase 
inhibitors, as have been confirmed by the direct inhibitory effect of iejimalides A and B 
on V-ATPase (Biosci. Biotechnol. Biochem. 70, 1364-1370). Furthermore, when 
different type of topo II inhibitors, etoposide and ICRF-193, which are known as a topo II 
poison and a catalytic inhibitor, respectively, were analyzed by the system, the 
compounds were clustered into different trees. This indicates a power of the system that 
discriminates compounds by mechanism of action. The expansion of the database of 
proteomic profiling by a 2D-PAGE will aid the characterization of numerous natural 
compounds in many aspects, such as mechanism of action, off-target effects, biomarking, 
and yet unknown target(s) identification.    
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EXPERIMENTAL PROCEDURES 
 
Materials 
Iejimalide A and B were obtained from Dr. Jun’ichi Kobayashi of Hokkaido 
University. Actinomycin D, brefeldin A, concanamycin A, cycloheximide, cytochalasin 
D, geldanamycin, radicicol, staurosporine and etoposide were provided by the NPDepo 
(RIKEN Natural Products Depository, http://www.npd.riken.jp/npd/). Bafilomycin A1, 
daunomycin, and tunicamycin were purchased from Wako Pure Chemical Industries 
(Osaka, Japan). Okadaic acid and nocodazole were purchased from Sigma (St. Louis, 
MO). Jasplakinolide, LY294002, MG-132, and vinblastine were from Calbiochem (La 
Jolla, CA). ICRF-193 was from Funakoshi Co. Ltd. (Tokyo, Japan). 
All compounds were dissolved in dimethylsulfoxide (DMSO) and stocked at -20°C. 
Monoclonal anti-HSP70 (clone C92F3A-5) and monoclonal anti-HSP27 (clone G3.1) 
were purchased from Stressgen Biotechnologies Corporation (British Columbia, Canada). 
Monoclonal anti-a-tubulin (clone DM1A) was purchased from Sigma (St. Louis, MO). 
The reagents for Western blotting were purchased from Thermo Scientific (Rockfort, IL). 
All reagents were reagent-grade. 
 
Cell Culture  
HeLa cells were cultured in Dulbecco's Modified Eagle’s Medium (D-MEM, Sigma, 
St. Louis, MO), supplemented with 10% fetal bovine serum, at 37°C in a humidified CO2 
incubator (5% CO2-95% air).  
  
Cell Growth Assay 
HeLa cells were seeded at 2 × 103 cells per well in a 96-well culture plate and 
incubated overnight, test compounds were added to the medium at various concentrations. 
After 48 h, cell number was determined using Cell Count Reagent SF (Nakalai Tesuque, 
Kyoto, Japan) according to the manufacturer’s protocol. Briefly, 10 µL of WST-8 
solution (mixture of WST-8 and 1-methoxy-5-methylphenazinium methylsulfate) was 
added to the wells and incubated for 2 h, and cell number was assessed by measuring the 
absorbance at 450 nm on a microplate reader (BIO-RAD, Hercules, CA) 
 
Preparation of Cell Lysates for Proteomic Analysis 
 16 
 HeLa cells (3 x 105 cells) were seeded on a culture dish (35-mm diameter) 
containing 3 mL of medium and incubated overnight. Each assay was done in triplicates. 
The cells were exposed for 18h to the designated concentrations of test compounds. Cells 
were washed thrice with ice-cold phosphate-buffered saline (PBS), removed by a rubber 
policeman and collected by centrifugation at 4000 rpm for 3 min at 4°C in a 
microcentrifuge (KUBOTA 3700, Kubota, Tokyo, Japan). 
 After being washed once with PBS, cells were suspended in sample buffer (7 M 
urea, 2 M thiourea, 4% CHAPS, 30 mM Tris, buffered to pH 8.5) for 2D-DIGE and 
disrupted with a TOMY UR-20P sonicator (TOMY Co. Ltd., Tokyo, Japan). Cell lysates 
were treated with 1.25 U/µL benzonase (Merk, Darmstadt, Germany) for 60 min on ice 
and centrifuged at 12,000 rpm for 3 min at 4°C. Supernatants were stocked at -80°C until 
use. 
 
Labeling of Cell Lysates and 2DE 
 Protein concentration was determined by Bradford procedure using the Protein 
Assay kit (BIO-RAD, Hercules, CA). Fifty micrograms of protein was labeled with 200 
pmol of CyDye DIGE Fluor minimal dyes (GE Healthcare, Buckinghamshire, UK) 
according to the manufacturer’s instructions (Cy3 and Cy5 for samples and Cy2 for 
internal control, consisting of equal parts of all samples in an experiment). 
 Samples were applied by rehydration onto immobilized pH gradient strips (24 cm, 
pH 3–10, nonlinear gradient, GE Healthcare) and subjected to isoelectrofocusing in an 
IPGphor IEF system (GE Healthcare). Strips were incubated in equilibration buffer (6 M 
urea, 30 % glycerol, 2% SDS, 50 mM Tris-HCl pH 8.8) containing 1% DTT for 15 min 
and then incubated in the same buffer containing 2.5% iodoacetamide for 15 min. Strips 
were transferred to the tops of 10% polyacrylamide gels and electrophoresed overnight in 
a DALT-twelveTM apparatus (GE Healthcare). 
 After electrophoresis, gels were scanned using a TyphoonTM 9400 imager at 100 dpi 
resolution (GE Healthcare). Gel analysis was performed using DeCyder BVA 6.5 (GE 
Healthcare), a 2DE analysis software package, following the manufacturer’s 
recommendations. The estimated number of spots for each codetection was set to 3000. 
 
Experimental Design and Data Processing for 2DE Profiling 
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 To perform visual 2DE protein profiling of compound-treated HeLa cells, 
experiments were divided into subsets. We used the spot number of the master gel as the 
common master number for all of the experiments. The gel that contained the most spots 
in the first experiment (analysis of HeLa cells treated with various concentrations of 
geldanamycin) was chosen as the master gel. 
 In a representative subset of experiments, we used 3 compounds and DMSO. HeLa 
cells were treated with these solutions, and proteomic analysis was performed. All 
samples of compound- and DMSO-treated cells were prepared in triplicate. Equal parts of 
all samples in a subset of experiments were labeled with Cy2 CyDye Fluor as an internal 
standard. 
 To match the common master numbers between subsets of experiments, image files 
were imported into the project file, including the master gel, and spot maps of the images 
were matched to the master gel image using the BVA modules of DeCyder 6.5. More than 
650 spots were usually matched in all the analyzed gels of a subset. The volume of each 
spot was obtained as a ratio of the Cy3- or Cy5-labeled sample compared with the 
corresponding Cy2 signal of the internal standard. Then, the volume of each spot was 
normalized using the average of the corresponding control value from the DMSO-treated 
HeLa cells. 
 Normalized volume data in subsets of experiments were combined, and only spots 
that did not lack data in any of the gels were selected. Subsequently, the spots that showed 
significant changes after compound-treatment were selected by ANOVA (P < 0.01) and 
Dunnett's test for post hoc analysis. For cluster analysis, the normalized volumes were 
calculated using the means of uncentered correlation with centroid linkage using Cluster 
3.0 (Hoon, et al., 2004) and visualized using Java TreeView (Saldanha, 2004). 
 Statistical calculations, such as nonrepeated measures ANOVA and Dunnett's test 
for post hoc analysis (Sheskin, 2000), were performed using Microsoft Excel with a 
statistical macro (ystat2006, Igaku Tosho Shuppan, Tokyo, Japan) and R version 2.9.2 
(http://cran.r-project.org/). 
 
Western Blotting 
Cell lysates were resolved by 10% SDS-PAGE and transferred to PVDF 
membranes. Membranes were blocked with 5% nonfat dried milk in TBS-T buffer (10 
mM Tris-HCl, pH 8.0, 150 mM NaCl, and 0.05 % Tween 20), followed by incubation 
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with primary antibody (1:1000 dilution) in TBS-T. The detection was performed using 
horseradish peroxidase-labeled secondary antibodies (1:1000 dilution) and enhanced 
chemiluminescence detection reagent. The expression of tubulin was also measured and 
used as an internal control. 
 
Flow Cytometry 
Cells were treated with 0.25% trypsin for 5 min to remove them from the dish, 
washed with PBS, fixed in cold PBS containing 70% (v/v) ethanol, and stored at -20°C 
overnight. Then, the cells were washed with PBS and incubated with a DNA-staining 
solution containing 50 mg/ml propidium iodide (Sigma Chemical Co., St. Louis, MO) and 
2 mg/ml RNase A at 4°C for 30 min. Total fluorescence intensities were determined by 
quantitative flow cytometry with Cytomics FC500 (Beckman Coulter, Miami, FL). 
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FIGURE LEGENDS 
 
Figure 1. Dose- and Time-Dependent Effects of Geldanamycin and Radicicol on HeLa 
Cells  
 (A) Geldanamycin or radicicol was added at the indicated concentrations and incubated 
for 48 h. Cell number was measured by WST-8 assay, as described in Materials and 
Methods. Bars, SD (n = 3). (B) HeLa cells treated with a compound at the indicated 
concentrations or with DMSO for 18 h were analyzed by 2D-DIGE. Hierarchical 
clustering was performed. Red, upregulated; green, downregulated. The spots identified 
by peptide mass fingerprinting (PMF) (Table S2) are indicated by an arrow, and the 
master number and gene name are shown. (C) Cell lysates incubated for 18 h with 
designated concentrations of geldanamycin or radicicol were analyzed by Western blot 
following SDS-PAGE using anti-HSP70, anti-HSP27, or anti-tubulin. (D) HeLa cells 
were incubated in the presence of 0.5 µM geldanamycin for the indicated times and 
analyzed by 2-D DIGE. Using the data of 91 spots selected as described in Materials and 
Methods, hierarchical clustering was performed. The spots designated by the arrow are 
the spots (no. 1114, no. 1127) identified as HSP70 by PMF. (E) Mean ratios of spots 114 
and 1127, determined in D, were plotted. Bars, SD (n = 3). 
 
Figure 2. Clustering of Well-Characterized Compounds and Iejimalides by Proteomic 
Analysis of HeLa Cells 
 (A) HeLa cells treated with compounds listed in Table 2 for 18 h were analyzed by 2-D 
DIGE. The position of each spot is designated by a red circle, and the master number of 
the spot is marked. (B) Hierarchical clustering was performed. The identified spots 
(Table 3) are designated by arrows. (C) HeLa cells were treated with 30 nM of iejimalide 
A and B. The quantitive data was combined with the data of 19 well-characterized 
compounds and hierarchical clustering was performed. 
 
Figure 3. Differential Phenotypes of HeLa Cells Treated with ICRF-193 and etoposide by 
Flow Cytometry.  
 The distribution of cellular DNA content of asynchronous HeLa cells treated with 
ICRF-193 or etoposide was determined by flow cytometry. HeLa cells were treated with 
the indicated concentrations of ICRF-193 (A) or etoposide (B) for 48 h. In a time course 
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experiment, HeLa cells were treated with 10 µM of ICRF-193 (C) or etoposide (D) for the 
indicated times. 
 21 
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Table 1. Expression Data of Identified Spots in HeLa Cells Treated with Geldanamycin or Radicicol. 
 
 Master number of spots and gene name of identified proteins 
 673 713 714 971 983 998 1114 1127 1295 1429 1484 1579 2014 2372 2382 
 HSP90AB1 EEF2 EEF2 HSPA5 HSPA5 HSPA9B HSPA1B HSPA1B HSPD1 CAP1 FSCN1 PDIA6 AKR1C2 HSPB1 HSPB1 
Geldanamycin 0.005 µM 1.02 0.97 0.95 1.03 1.01 0.95 1.05 1.10 1.02 0.96 0.97 1.04 0.95 1.04 0.98 
Geldanamycin 0.05  µM 0.97 0.93 0.95 1.07 1.04 1.03 2.74** 3.40** 1.19* 0.96 0.96 1.02 0.91* 1.41* 1.43** 
Geldanamycin 0.5   µM 1.29** 0.71** 0.63** 2.26** 1.29* 1.39** 7.22** 8.94** 1.75** 0.61** 0.71** 1.19** 0.66** 2.38** 1.90** 
Geldanamycin 5    µM 1.31** 0.66** 0.59** 5.90** 2.70** 1.31** 7.33** 9.20** 1.62** 0.39** 0.72** 1.44** 0.69** 2.48** 1.82** 
Geldanamycin 10   µM 1.41** 0.70** 0.55** 5.72** 2.71** 1.41** 8.05** 9.26** 1.64** 0.40** 0.71** 1.42** 0.66** 2.64** 1.75** 
Radicicol    10   µM 1.19* 0.82* 0.72** 2.60** 1.28* 1.28* 7.43** 9.39** 1.34** 0.55** 0.75** 1.07 1.06 2.11** 1.65** 
 
The mean ratios of identified spots between control and compound-treated cells are listed. Non-repeated measures ANOVA and Dunnett's test for post hoc analysis were performed. 
Asterisks indicate significant differences from respective controls (* P < 0.05,  ** P < 0.01). 
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Table 2. Compounds for Proteomic Analysis by 2D-DIGE 
 
Compounds Target IC50 (µM)a Conc. (µM)b Ref 
Actinomycin D RNA synthesis  0.0022  0.015 Sobell, 1985 
Bafilomycin A1 V-ATPase  0.0035  0.01 Bowman, et al., 1988 
Brefeldin A Protein transport  0.023  0.05 Klausner, et al., 1992 
Concanamycin A V-ATPase  0.002  0.005 Huss, et al., 2002 
Cycloheximide Protein synthesis  0.17  2 Obrig, et al., 1971 
Cytochalasin D Actin  0.32  1 Cooper, 1987 
Daunomycin DNA synthesis  0.034  1 Aubel-Sadron and Londos-Gagliardi, 1984 
Etoposide Topoisomerase II  3 50 Liu, 1989 
Geldanamycin HSP90  0.18  0.5 Whitesell, et al., 1994 
ICRF-193 Topoisomerase II  2 50 Roca, et al., 1994 
Jasplakinolide Actin  0.038  0.1 Bubb, et al., 1994 
LY294002 PI3 kinase 12 42 Vlahos, et al., 1994 
MG-132 Proteasome  0.24  1 Lee, D.H., and Goldberg, A. L. 1998 
Nocodazole Tubulin  0.027  5 Lin and Hamel, 1981 
Okadaic acid Phosphatase  0.014  0.03 Bialojan and Takai, 1988 
Radicicol HSP90  2.1  10 Schulte, et al., 1998 
Staurosporine Protein kinase  0.03  0.3 Rüegg and Burgess, 1989 
Tunicamycin N-linked oligosaccharide synthesis  0.27  5 Takatsuki, et al., 1971 
Vinblastine Tubulin  0.0031  0.01 Rai and Wolff, 1998 
a The 50% inhibitory concentration of HeLa cell growth.  
b Concentrations used for proteome analysis 
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